K. C. Demel
All authors
About
Publications While At HealthPartners
selected publications
Abstract
CT066 / 16 - Phase 1 study of MDM2 antagonist ASTX295 in patients with solid tumors with wild-type TP53 [abstract]
2024
Phase 1/2 trial of the HPK1 inhibitor NDI-101150 as monotherapy and in combination with Pembrolizumab: clinical update [abstract]
.
Journal of Clinical Oncology.
2024
Contact
full name
K. C.
Demel
Quick Info
Collaboration
Co-author network
Map of science
